Tamoxifen therapy in breast cancer control worldwide.
Richard R. Love1 and Valentin Koroltchouk2
1Professor, Departments of Human Oncology, Medicine, and Family Medicine and Practice,University of Wisconsin - Madison. Mailing address: 7C, 1300 University Avenue, Madison,WI 53706, USA
2Scientist, Cancer and Palliative Care Unit, World Health Organization, Geneva, Switzerland. Mailing address: World Health Organization, 20 Avenue Appia, CH-1211 Geneva 27,Switzerland
In 1980 breast cancer was estimated to be the most frequent major cancer in women worldwide.
Incidence and mortality appear to be increasing in developed countries. Disease prevention is
undefined or postulated strategies are impractical. When breast cancer progresses to metastatic
stage, it is incurable and the impact of palliation on duration of life is limited. With early stage
regional disease, local treatment combined with adjunctive hormonal treatment with tamoxifen
can save 6 women out of 100 from death compared with local treatment alone. Tamoxifen is a
synthetic estrogen with antiestrogenic effects on breast cancer cells but estrogenic effects on
liver metabolism and bone with resultant decreases in risk factors for chronic diseases of the
vascular system and skeleton. With long term tamoxifen treatment major clinical adverse effects
occur in under 5% of women; symptomatic menopausal-vasomotor symptoms occur in a
majority of treated women, but lessen over time. In controlling breast cancer more successfully
worldwide one challenge is to bring tamoxifen therapy to greater numbers of women.
Breast cancer in women is a growing global health problem for which a hormonal treatment -
tamoxifen - can provide part of the answer. This report briefly reviews the dimensions of the
worldwide breast cancer problem, and the available data which support the case that more
widespread application of tamoxifen treatment is justified. Finally the challenges in achieving
this goal and the new broad research agenda to be addressed are identified. Breast cancer worldwide: cases, incidence, morality and trends.
In 1980 breast cancer was the most common major cancer in women worldwide with an
estimated 572,100 cases, 18.4% of all cancers in women (1). The next most frequent cancers in
women were those of the uterine cervix (15.0%) and colon/rectum (9.2%). Current estimates are
that 750,000 new cases will be diagnosed in 1993 and as many as 1 million new cases annually
will be recorded at the turn of the millennium. Sixty percent of these cases occur in women in
developed countries (1) and two thirds or greater occur in women over 50 years of age.
While various factors contribute to changes in estimated disease specific incidence and mortality,
and these are difficult to identify or adjust for if appropriate, it appears that particularly in
western developed countries the incidence of breast cancer is increasing. Mortality also appears
to be increasing (2) although not in all developed countries. Mortality rates in some western
countries remain about one third of incidence rates. Among western women with the highest
incidence rates, at age 40 approximately one woman in 1000 develops breast cancer each year,
while at age 60 this rate has increased to one woman in 500. At these rates, in a group of healthy
40 year old women 3.3% will develop breast cancer before age 60 (3). Dimensions of the challenges of breast cancer control.
In the face of the increasing problems which these foregoing numbers, rates and trends portray,
what strategies are available or developing which can be applied worldwide? While many
causative or risk factors for breast cancer are well defined, these data appear fragmented because
they do not fit well together in complete models for disease development. While additionally,
few causative factors are easily manipulable, two recently receiving more attention are worthy of
comment. Some data implicate active and passive (4,5) cigarette smoking in breast cancer
development. These are of particular concern because of the high and increasing prevalence of
smoking in developing countries and provide another cogent reason for more vigorous attention
to the tobacco epidemic. Second, more data are becoming available suggesting that long
duration lactation is significantly protective against breast cancer (6). This information should
be more widely used in public health programs worldwide. With these exceptions practical
interventions to prevent breast cancer are not currently available.
At advanced stages, breast cancer is currently a disease for which palliation is the most
practicable approach. The reasons for the refractionness of metastatic breast cancer to
significantly life-prolonging treatment are multiple: (1) The evolution of the disease over several
years has preceded this state during which time increasingly malignant clones of tumor cells can
develop; (2) Heterogeneity of the disease, whose recognition and implications have yet to be
well defined and understood prevents optimal individual-specific treatment; (3) Most
importantly, an absence of adequately effective - "curative" therapies separates breast cancer
from other malignancies for which remarkably effective drugs have been identified empirically.
While our knowledge of breast cancer biology has grown exponentially in recent years, and our
abilities to apply currently available techniques of drug dose density, bone marrow
transplantation, and biological response modifiers have increased, practical life-prolonging
therapies for populations are yet to be defined.
While all cases of clinical breast cancer are diagnosed after several years in development, and
thus "late," detection when the primary breast tumor is smaller is associated with a lower
likelihood of regional spread of disease and lower stage, and confers a better prognosis.
Practical strategies to "downstage" disease in populations are likely to have benefit in reducing
mortality. In developed, particularly western countries, screening mammography has been the
most discussed downstaging strategy. Recent data confirm however that mammography is of no
benefit in premenopausal women (7) and suggest that when combined with careful breast
examination, mammography is of modest only benefit in women 50-59 (8). Thus at present the
most practical population-benefitting approach is a low technology one: increasing the
proportion of women who have regular breast examinations.
In developed countries the vast majority of women with breast cancer present with regional
disease whose initial treatment is with ablative surgery or limited surgery plus radiotherapy. A
major fraction of these women however are destined to develop clinically evident metastatic
disease ultimately, disease present in a subclinical, micrometastatic form at the time of initial
diagnosis. With the development of data from rigorous randomized controlled clinical trials, it
has become clear that adjuvant, that is additional, systemic treatment at diagnosis can decrease
the risks of developing metastatic disease and dying from breast cancer. A comprehensive
overview analysis of these studies has shown that polychemotherapy for premenopausal women
reduces the annual risks of recurrence by 29% and of mortality by 16% (9). [A 15% annual risk
reduction means that 4-6 additional women in 100 will be alive after 10 years as a result of
therapy.] This overview also suggests similar magnitudes of benefit from surgical or radiation
oophorectomy in premenopausal women, although this conclusion is based on much smaller
numbers of treated women with heterogenous stages of cancers and probably should be regarded
as hypothesis-generating rather than conclusive evidence for this adjuvant strategy (10). In
population terms, the relevance and application of the polychemotherapy data are somewhat
uncertain. First, despite convincing evidence of benefit from individual trials and the overview
analysis, the evidence for benefits to populations where adjuvant polychemotherapy has been
widely applied is weak. Second, the practice of adjuvant polychemotherapy is very technical and
expensive and on these grounds direct application to women in developing countries is
impractical. Finally, the vast majority of the clinical trials have been accomplished exclusively
in western women usually of higher socio-economic and caucasian groups, and the relevance of
these conclusions to poorer women of other ethnic groups must be considered uncertain.
In contrast to the polychemotherapy adjuvant therapy results, the adjuvant tamoxifen results may
have more widespread application and the aspects of this are the focus of the remainder of this
In summary, the current public health challenges of breast cancer control, aside from the more
widespread application of tamoxifen adjuvant therapy, are to apply limited data about tobacco
and lactation to prevention and to increase the frequency of breast examinations to downstage
Tamoxifen as adjuvant treatment: evidence for efficacy.
The case for more widespread application of adjuvant tamoxifen therapy must rest on the qualityof the evidence for efficacy, particularly in reducing mortality. This case is extraordinarilystrong because of the large number of individual randomized clinical trials which have beenreported - 40 - or are not yet available - 4 - which have given a consistent picture of the favorableeffects as well as a rigorous meta-analysis of these trials which has confirmed their conclusions(10). For purposes here it seems most reasonable to refer to the overview/meta-analysis resultsbecause in the case of adjuvant tamoxifen trials these data are hypothesis-supporting (and nothypothesis generating) because the individual trials on which they are based alsooverwhelmingly show the same conclusions individually. In addition, these overview dataprovide quantitative and qualitative perspectives which are critical to judgements about morewidespread applicability.
In Figure 1 is reproduced the essential results of short term (in the majority 2 years maximum)adjuvant tamoxifen therapy. While modest, the figure results indicate that approximately 4 toand 6 additional women in 100 will be alive after 5 and 10 years consequent to this treatment. The percentages of additional women who are alive but with recurrence of disease are 8% and6.5% at 5 and 10 years respectively. Thus when considered on a population basis, this treatmentcan prolong and save the lives of many women with early stage breast cancer.
The numbers discussed so far present the overall picture. Of interest is whether further data onsubsets of treated women provide clarifying information which defines more precisely where toapply this treatment to achieve the greatest benefits. Table 1 summarily addresses some of the important issues. In these trials there do not appear tobe any dose differences and so the lowest dose widely used, 20 mg daily, can be regarded asstandard. The data on duration are incomplete; the majority are for treatment periods of 2 years. It is remarkable that despite an apparent cytostatic mechanisms of action (see below), there ispersistence of benefit seen many years after cessation of therapy, with in fact a widening of themortality differences between treated and untreated groups of women between 5 and 10 years. The overview data suggest greater benefit with longer duration of treatment, but at present twoyears must be considered a reasonable standard. While absolute benefits are greater to womenwho have axillary node metastases and who have tumors with positive or higher measurablelevels of estrogen receptors, women with no axillary metastases and low or absent levels ofestrogen receptors in their tumors also derive significant benefits from treatment.
The effects of adjuvant tamoxifen in women who are premenopausal or postmenopausal, underor over 50 years of age are qualitatively similar. In general, younger women appear to benefitless from adjuvant tamoxifen (Table 1 compared to Figure 1) and in considering strategies forpopulations based on available data, a case can be made that other adjuvant therapeuticapproaches such as surgical oophorectomy should be considered, although for this there are farfewer data presently.
For older women, for whom the incidence of breast cancer is greater, the benefits of adjuvanttamoxifen are quantitatively and qualitatively similar.
Do the available data for tamoxifen differ with respect to a broad case for application topopulations, from these for polychemotherapy in premenopausal women presented earlier?
Ten-year Mortality in Tamoxifen Trials: Overall Results for 30,000 Women (9). Magnitudes of mortality benefits of adjuvant tamoxifen with different doses, duration, different nodal status, and in different primary tumor estrogen receptor categories.*
* Abstracted from Table III Lancet 339:1-15, 1992 (10)
**Absolute benefits: If 100 node positive women have persistent reduction in annual odds ofdeath of 15%, 6 additional women, if 30%, 12 additional women, will be alive after 10 years.
It is the case that clear evidence of benefits to populations from adjuvant tamoxifen is not
available. If one accepts that the prevalence of adjuvant tamoxifen use in some western
countries is high, possible explanations for the absence of population benefit are several but lie
chiefly in confounding of this effect by rising incidence. Tamoxifen therapy is a daily oral
treatment and thus less technically complex, but costs remain high in some western countries.
Finally, some of the subjects in tamoxifen trials have been Asian women, but tamoxifen also
must be considered to be significantly under-evaluated in developing countries, and nonwestern
With a strong case for benefits in mortality reduction and disease free survival increases from
adjuvant tamoxifen, a more comprehensive review of biological effects, other benefits, toxicities,
and symptomatic sequelae of tamoxifen treatment is important to further place in context the
Biology and non-breast cancer effects of adjuvant tamoxifen treatment.
Tamoxifen is a synthetic estrogen with estrogen agonist and antagonist properties (11). It was
originally developed as an oral contraceptive, in which role it is ineffective, and it was then
found serendipitiously to be effective in palliating some women with metastatic breast cancer.
Over the last 20 years the drug has been used in that setting, but also increasingly as adjuvant
The pharmacology of tamoxifen is remarkably complex. After oral administration maximal
blood levels are reached in 4-7 hours, and a steady state of drug levels in the blood is achieved
after 4 weeks. It takes 6-8 weeks for all serological evidence of tamoxifen and its metabolites to
disappear from the blood. While the teratogenicity of tamoxifen is unknown, this is important in
premenopausal women who may become pregnant while taking the drug because even if it is
stopped, the fetus is likely to receive continuous exposure during the entire first trimester.
Tamoxifen is metabolized by the liver, excreted in bile and eliminated from the body in feces. In
postmenopausal women, gonadotropin decreases are seen with tamoxifen therapy; estrogens,
progesterone and prolactin levels do not change. In contrast in premenopausal women large
increases in total estrogens, estradiol and progesterone occur in some women.
At the cellular level tamoxifen is considered to exert its effects by combining with nuclear
estrogen receptor protein with resultant arrest of breast cancer cells in the G1 phase of the cell
cycle. Thus tamoxifen appears to be a cytostatic instead of a cytocidal agent. This concept is
supported by some of the adjuvant trial data, but the prolonged effect data referred to earlier
suggest more complex effects. Changes in various biological growth mediators are also seen
with tamoxifen treatment: sex hormone binding globulin levels increase (which can remove
more free estrogen from the circulation); transforming growth factor alpha levels decrease (a
growth stimulatory protein); and transforming growth factor beta levels increase (a growth
inhibitory protein). Effects in breast stromal cells have been suggested to mediate tamoxifen's
action in neighboring breast cancer cells.
In summary, tamoxifen is a synthetic estrogen which might be expected to have direct estrogenic
effects, but also has estrogen antagonist effects. In addition it causes hormonal and growth
factor perturbations whose long term consequences can be expected to be profound. The largest
use of tamoxifen in humans has been as adjuvant treatment. In these trials reviewed above, the
focus has been on recurrence and survival from breast cancer. It is only recently that greater
attention has been given to the possible non-breast organ, tissue and risk factor effects of this
Cardiovascular and skeletal effects.
Hormones exert powerful effects on several organ systems. In western women, where more
studies have been done, the most profound effects are on the cardiovascular and skeletal systems.
Women who survive to undergo menopause become at major risk for chronic diseases of these
systems; indeed almost half of women in these societies who pass their fiftieth birthdays will
ultimately die of cardiovascular disease. Another large, difficult-to-estimate fraction will suffer
from skeletal fractures of osteoporotic bones. These chronic diseases are reflections of marked
changes in risk factors which occur following menopause with associated marked decreases in
ovarian hormones. In this context then, what is known of the actions of tamoxifen?
The effects of tamoxifen on risk factors for cardiovascular disease appear to be generally
favorable and estrogenic. Controlled studies show decreases in levels of total and low density
lipoprotein cholesterol, fibrinogen and platelets, and an absence of major changes in blood
pressure or glucose metabolism in postmenopausal women (12) (Figure 2). That these
consequences of tamoxifen treatment are clinically important is suggested by the results of the
meta-analysis of tamoxifen adjuvant studies in which a 25% reduction in vascular deaths was
found (10), and by analysis of one trial in which major reduction in numbers of postmenopausal
women with myocardial infarction was found (13). While these observations are consistent with
the risk factor changes, they should be regarded more as hypothesis-generating than hypothesis-
confirming, and in particular their postmenopausal population base should be noted.
The effects of tamoxifen on bone mineral density, a major measure of risk for fracture, are also
likely to be favorable. The decline in bone mass associated with the cessation of ovarian
estrogen production involves mainly the more metabolically active trabecular bone found in the
spine and to a lesser degree in the hips. In postmenopausal women tamoxifen clearly has a bone
density-preserving effect in the lumber spine (14) (Figure 3). This observation is consistent with
animal data which suggest that tamoxifen is an antiresorptive agent like estrogen and thus may
be associated over time with decreased rates of fracture. Mean fasting levels (± standard error) of total cholesterol over time in postmenopausal patients receiving tamoxifen or placebo (12). (Reproduced with permission.) Change in mean (± standard error) lumbar spine bone mineral density in postmenopausal women receiving tamoxifen or placebo (14). (Reproduced with permission.)
Other significant and undefined effects.
Because the major sources of data about the effects of tamoxifen have been the adjuvant trials
which were designed for cancer endpoints evaluation, a complete picture of consequences of this
therapy is not yet available. These trials and the meta-analysis will nevertheless continue to
provide major data. While the long list of incompletely defined effects in Table 2 should prompt
caution and further evaluation and research, these uncertainties must be placed in context. With
adjuvant tamoxifen treatment, recurrence of breast cancer and death are unquestionably averted
in postmenopausal women, and probably in premenopausal women (Table 1 and Figure 1). In
the overview analysis the vast majority of deaths were from breast cancer; thus while there may
be morbidity from tamoxifen treatment as yet incompletely recognized, and possible long term
mortality effects, over a 5-10 year period after diagnosis of breast, cancer death and death from
all causes are averted with this treatment. As reviewed above for the major chronic diseases of
western women over 50, tamoxifen appears, if anything, to be protective.
The breadth of data which have generated the possible - hypothetical effects listed in Table 2
cannot be reviewed here, but the rationales for the particular entries deserve comment. Other
reviews which can be useful are referenced (15).
Hormonal effects on uterine tissues, the liver and most recently on the colorectum can be to
promote tumor growth. There are very limited data at present which support the case that these
are of numerically significant if at all real concern. The growth factor-altering effects of
tamoxifen may protect against hematopoietic malignancies. Depression does occur with
tamoxifen; its frequency is poorly described. Thrombophlebitis appears to occur at excess rates
of 1/800 women treatment years; risk factors for this complication are undescribed. While some
good quality lipid, fibrinogen, and platelet data are available for postmenopausal women, further
lipoprotein, blood pressure and glucose data are needed because minor changes in these may be
critical to risk for cardiovascular disease and manipulable. Whether various ocular conditions
are increased infrequency with tamoxifen is unknown; some data have prompted more careful
study (16). Since estrogen therapy is associated with increased rates of cholelithiasis and
tamoxifen has similar effects on lipid and lipoproteins, rates of cholethiasis on tamoxifen are
worthy of evaluation. The effects of hormones like tamoxifen on the immune system are of
increasing interest. In one Swedish study hospitalization rates for immune disorders were lower
in tamoxifen-treated women. Bone mineral density changes at other sites than the lumbar spine
With hepatic metabolism and binding to different body tissues and proteins, possible interaction
of tamoxifen with other drugs used at varying frequency in different populations warrants
Finally, tamoxifen is not a curative adjuvant therapy. Many women develop recurrences of
breast cancer - metastatic disease while taking tamoxifen. The mechanisms of this tamoxifen
resistance and the optimal management of these patients are just beginning to receive attention
(17). It is however notable that rates of second primary i.e. contralateral, breast cancer are
significantly lower with tamoxifen treatment; the overview found a 39% reduction in these
There are additional effects of particular concern in younger premenopausal women. In the main
this has been because fewer premenopausal women have been included in adjuvant trials. Of
greatest concern are the possibilities that the direct and indirect hormonal effects of tamoxifen
may be carcinogenic to the breast and ovary in younger women. Specifically here available data
indicate that tamoxifen markedly increases estrogens in some women at frequencies
incompletely described, and is associated with an increase in contralateral breast cancer in one
trial (18). Epithelial ovarian cancer is a disease affected by factors that influence ovulation or
epithelial disruption which tamoxifen does in increasing this event. Specific cardiovascular
effects are completely unevaluated in premenopausal women, and gynecologic effects are poorly
described. The details and risk factors for vasomotor symptoms are also poorly described.
Finally, how to optimally achieve contraception and the actual risks of teratogenesis are
unknown and important issues for premenopausal women.
Again these uncertainties (Table 2) define issues which deserve particular research attention and
monitoring with the more widespread use of adjuvant tamoxifen justified by the significant
mortality benefits, particularly in postmenopausal women. Indeed because of the likely rarity of
most of the serious consequences, it will only be through population monitoring that any
Effects of tamoxifen which are incompletely defined.
Uterine endometrium carcinogenicUterine myometrium carcinogenicLiver carcinogenicColon-rectum carcinogenicHematopoietic: carcinogenic/protectiveCentral nervous system: mood alteringCoagulation: thrombophlebitisCardiovascular: lipoprotein, blood pressure, glucoseEye: macular, retinal, lensHepatobilary: cholelithiasisImmune system: functionalDrug interactionsSkeletal: bone mineral density changes at all sitesBreast cancer: treatment of recurrence
Ovary: carcinogenicBreast: carcinogenicHormonal: patterns, levels and frequency of changesCardiovascular: lipid, fibrinogen, plateletGynecologic: symptomatic, infectiousVasomotor: symptomaticPregnancy: teratogenic, contraception
Contraindications to adjuvant treatment with tamoxifen.
In practical terms there are few women, particularly postmenopausal women, who have histories
which should prevent them from taking tamoxifen. In Table 3 are summarized the suggested
absolute and relative contraindications. While certainty about retinal macular changes
consequent to tamoxifen is lacking, it is a possible side effect and the seriousness of these
conditions would seem to warrant particular prudence (16). The other absolute contraindications
are based on concerns regarding hormonal carcinogenesis, teratogenesis, and inefficacy of
tamoxifen therapy for breast cancer respectively.
The relative contraindications identify conditions which may be major risk factors for major
complications. The drugs listed can have retinal toxicity and this may be synergistic with
tamoxifen in producing ocular conditions. Tamoxifen invariably increases the number and
intensity of vasomotor symptoms, and in postmenopausal women possibly one third develop
annoying gynecologic symptoms (19). For some women who have these symptoms before
tamoxifen therapy is begun and who are proscribed estrogen therapy because of their breast
cancer, the increments in these symptoms may be intolerable. Contraindications to adjuvant tamoxifen.
Retinal macular edema or degenerationHistory of benign or malignant liver tumor secondary to oral contraceptivesPregnancyOther hormonal therapy (estrogens, oral contraceptives)
History of thrombophlebitis, particularly hormone relatedHistory of depression, particularly hormone relatedCataract
Drugs: Chlorpromazine, chloroquine, thioridazine, amiodarone, other
Severe vasomotor symptomsPolycystic ovaries
Widespread use of adjuvant tamoxifen: benefits and challenges.
In the year 2000, if one million women per year are diagnosed with breast cancer and the large
majority of these cases can be diagnosed in lower stages, then available data suggest that 60,000
of these women could be saved from death by adjuvant tamoxifen treatment and many thousands
more will have recurrence and death from breast cancer delayed. While this crude estimate of
potential benefits from widespread application of adjuvant therapy is based on extensive clinical
trial data, there are clearly major gaps in our knowledge and systems which must be addressed if
such benefits are to be realized in populations.
The major challenges are summarized in Table 4. Clinical research is needed to address four
issues to help define public health efforts likely to be most beneficial. While the postulated
magnitude of benefit is based on a two-year course of tamoxifen, some data suggest longer
treatment provides greater benefits. With further information on precise benefits with different
durations of treatment as well as other "costs," a cost benefit curve can be drawn to allow
approximate definition of a rational public health approach. At present the data for
premenopausal women are insufficient to support adjuvant tamoxifen use as a priority effort for
this subgroup. There are very few rigorous data in nonwestern populations, and various biologic
data suggest that assuming similar or in fact any benefit from adjuvant tamoxifen in other
populations is hazardous. The clinical research questions can be addressed simultaneously with
some application questions. For example, international collaborative programs which combine
clinical and applications research in developing countries can address multiple challenges. To
give a specific example, in a nonwestern developing country in which pill taking presents
problems, a large clinical trial of a depot preparation of tamoxifen might be evaluated as part of a
comprehensive breast program in which delay in presenting for diagnosis is studied and careful
assessment of medical resource use is undertaken. Clinical trials as a focus for quality improving
educational programs offer a means of actively involving physicians and other health care
workers in public health problem solving, as well as care giving in their own countries. Because
limited health care financial resources only are available in any country, agreements with major
pharmaceutical companies must be developed to provide large amounts of drug at lower than
current western prices. In addition, in individual countries precise quantitation of population-
wide benefits will allow placing of this center control approach rationally in the list of priorities
developed under rigorous National Cancer Central plans. Finally, since the benefits of adjuvant
tamoxifen are more likely to be limited with Stage III or regionally advanced breast cancer,
which is often the most common presentation of this cancer in developing countries, breast
cancer programs with combine greater educational efforts or examination frequency to
downstage disease at diagnosis along with greater availability of tamoxifen are likely to provide
In summary, the applications challenges are those of defining appropriate cost beneficial
strategies for adjuvant tamoxifen use unique to each country. Major challenges in increasing adjuvant tamoxifen use for women with breast cancer worldwide.
Definition of optimal duration of treatment
Increased definition of known adverse effects and their incidence
Further data on breast cancer benefits in premenopausal women
Data on breast cancer benefits in nonwestern populations
Development of injectable "depot" treatment
Quantitation of benefits for use in National Cancer Control Planning
Public health strategies which combine downstaging and adjuvant tamoxifen
Breast cancer is a growing global health problem for which a hormonal treatment - tamoxifen -
can provide part of the answer. Breast cancer is the most common major malignancy in women
and may account for 1 million cases by the year 2000. Sixty percent of cases occur in developed
countries and the incidence is increasing. Currently prevention of breast cancer is impractical,
but tobacco control may play a more important role in development of this disease than has been
previously appreciated, and long duration lactation appears to be significantly protective.
Downstaging of disease at presentation for diagnosis is an important strategy to limit mortality
Tamoxifen treatment as an adjuvant to loco-regional measures, has been demonstrated in many
separate randomized clinical trials and in a meta-analysis of 40 trials in 30,000 women, to have
significant benefits. Ten years after diagnosis approximately 6 women out of 100 treated with
tamoxifen will be saved from death and recurrence of breast cancer will be delayed for many
others. The preponderance of data available are for postmenopausal women; in premenopausal
women the beneficial effects are smaller. Qualitatively there are no subgroups of women who do
not appear to benefit from tamoxifen treatment; in particular, older women > 70 benefit also.
Tamoxifen has estrogenic and antiestrogenic effects. Fortunately its effects on risk factors for
cardiovascular disease and osteoporosis in postmenopausal women appear to be favorable. Total
and low density lipoprotein cholesterol are lowered, and bone mineral density in the lumbar
spine is preserved with treatment. These effects are suggested to decrease the likelihood of
cardiovascular disease and osteoporotic bone fractures which are the major causes of mortality
and morbidity in older women in developed countries. While overall mortality benefits are
demonstrated with tamoxifen treatment, a significant number of hypothesized or suggested
mostly adverse, but some favorable effects of this hormonal treatment remain at present
undefined. Greater concern lies in the absence of comprehensive data for premenopausal
women. There are few rare contraindications to tamoxifen: retinal macular edema or
degeneration, other hormonal treatment and pregnancy. While the clinical trials data would
strongly support more widespread application of adjuvant tamoxifen treatment, clinical research
is needed to address questions regarding optimal duration of treatment, occurrence of adverse
side effects and breast cancer benefits in premenopausal and nonwestern populations. To bring
tamoxifen to populations and move to the goal of averting possibly 60,000 premature deaths per
year from breast cancer worldwide, will require public health programs which explore the use of
depot injectable treatments, carefully quantify the population benefits of this intervention, and
which work also to increase the prevalence of lower stage disease at diagnosis. Clinical trials are
advocated as a mechanism for actively involving health care workers in definition of new
strategies for bringing adjuvant tamoxifen to more women with breast cancer. References
Parker, I.M., Laara, E., Muir, C.S. Estimates of the worldwide frequency of sixteen
major cancers in 1980. Int J. Cancer 41:184-197, 1988.
Stjernsw‰rd, J., Stanley, K.E., Hansluwka, H., Lopez, A.D. Progress against cancer?
Love, R.R. The risk of breast cancer in American women. JAMA, 257(11):1470, 1987.
Hirayama, T. Health effects of active and passive smoking. In: Smoking and Health
1987. Aoki, M., Hisamian, S., Taminoga, S. Eds. Elsevier, Amsterdam 1988,
Palmer, J.R., Rosenberg, L., Clark E.A., et al. Breast cancer and cigarette smoking: an
hypothesis. Am J. Epidemiology 134:1-13, 1991.
Luan, J.M., Yu, M.C., Ross, R.K., et al. Risk factors for breast cancer in Chinese women
in Shanghai. Cancer Res 48:1949-1953, 1988.
Miller, A.B., Baines, C.J., To, T., Wall, C. Canadian National Breast Screening Study:
1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med
Miller, A.B., Baines, C.J., To, T., Wall, C. Canadian National Breast Screening Study: 2.
Breast cancer detection and death rates among women aged 50 to 59 years. Can Med
Early breast cancer trialists' collaborative group, Systemic treatment of early breast
cancer by hormonal, cytotoxic or immune therapy. Lancet 339:72-85, 1992.
Early breast cancer trialists' collaborative group. Systemic treatment of early breast
cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1-15, 1992.
Love, R.R. Tamoxifen therapy in primary breast cancer: biology, efficacy and side
effects. J Clin Oncology 7:803-15, 1989.
Love, R.R., Wiebe, D.A., Newcomb, P.A. Effects of tamoxifen on cardiovascular risk
factors in postmenopausal women. Ann Int Med 115:860-4, 1991.
McDonald, C.C., Stewart, H.S. Fatal myocardial infarction in the Scottish adjuvant
tamoxifen trial. BMJ 303:435-7, 1991.
Love, R.R., Mazess, R.B., Barden, H.S., et al. Effects of tamoxifen on bone mineral
density in postmenopausal women with breast cancer. New Engl J Med 326:852-6, 1992.
Nayfield, J.G., Karp, J.E., Ford, L.G, et al. Potential role of tamoxifen in prevention of
breast cancer. J Natl Cancer Institute 83:1450-59, 1991.
Pavlidis, N.A., Petris, C., Briassoulis, E., et al. Clear evidence that long term low dose
tamoxifen treatment can induce ocular toxicity. Cancer 69:2961-64, 1992.
Touchette, M. Tamoxifen resistance in breast cancer. J NIH Res 4:67-72, 1992.
Houghton, J., Riley, D., Baum, M. The NATO and CRC trials of adjuvant tamoxifen
therapy. In: Long-term tamoxifen treatment for breast cancer. Ed: V.C. Jordan,
University of Wisconsin Press, Madison, WI (in press).
Love, R.R., Cameron, L., Connell, B.L., Leventhal, H. Symptoms associated with
tamoxifen treatment in postmenopausal women. Arch Int Med 151:1842-47, 1991.
FICHA TÉCNICA O RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO 1. NOMBRE DEL MEDICAMENTO Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG 2. COMPOSICIÓN CUALITATIVA Y CUANTITATIVA Cada ml de solución contiene 50 mg de fluorouracilo (como sal sódica formada in situ ). Cada vial de 5 ml contiene 250 mg de fluorouracilo. Cada vial de 10 ml contiene 500 mg de f
FAMILY CAREGIVING STATISTICS Published by: More than one quarter (26.6%) of the adult population has provided care for a chronically ill,disabled or aged family member or friend during the past year. Based on current census data,that translates into more than 50 million people. Source: National Family Caregivers Association (NFCA) RandomSample Survey of 1000 Adults, Funded by CareThere.co